159 related articles for article (PubMed ID: 37668173)
1. Long-term safety of tenapanor in patients with irritable bowel syndrome with constipation in the T3MPO-3 study.
Lembo AJ; Friedenberg KA; Fogel RP; Edelstein S; Zhao S; Yang Y; Rosenbaum DP; Chey WD
Neurogastroenterol Motil; 2023 Nov; 35(11):e14658. PubMed ID: 37668173
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1).
Chey WD; Lembo AJ; Rosenbaum DP
Am J Gastroenterol; 2020 Feb; 115(2):281-293. PubMed ID: 31934897
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2).
Chey WD; Lembo AJ; Yang Y; Rosenbaum DP
Am J Gastroenterol; 2021 Jun; 116(6):1294-1303. PubMed ID: 33337659
[TBL] [Abstract][Full Text] [Related]
4. Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial.
Chey WD; Lembo AJ; Rosenbaum DP
Am J Gastroenterol; 2017 May; 112(5):763-774. PubMed ID: 28244495
[TBL] [Abstract][Full Text] [Related]
5. Tenapanor hydrochloride for the treatment of constipation-predominant irritable bowel syndrome.
Zielińska M; Wasilewski A; Fichna J
Expert Opin Investig Drugs; 2015; 24(8):1093-9. PubMed ID: 26065434
[TBL] [Abstract][Full Text] [Related]
6. Abdominal Symptom Improvement During Clinical Trials of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation: A Post Hoc Analysis.
Lembo AJ; Chey WD; Harris LA; Frazier R; Brenner DM; Chang L; Lacy BE; Edelstein S; Yang Y; Zhao S; Rosenbaum DP
Am J Gastroenterol; 2024 May; 119(5):937-945. PubMed ID: 38294158
[TBL] [Abstract][Full Text] [Related]
7. A pharmacokinetic evaluation of tenapanor for the treatment of irritable bowel syndrome with constipation: an update of the literature.
Currò D; Ianiro G; Gasbarrini A
Expert Opin Drug Metab Toxicol; 2023 Dec; 19(12):889-894. PubMed ID: 38108081
[TBL] [Abstract][Full Text] [Related]
8. Tenapanor for the treatment of irritable bowel syndrome with constipation.
Sinagra E; Rossi F; Raimondo D; Conoscenti G; Anderloni A; Guarnotta V; Maida M
Expert Rev Clin Pharmacol; 2020 May; 13(5):473-479. PubMed ID: 32478632
[TBL] [Abstract][Full Text] [Related]
9. Tenapanor for constipation-predominant irritable bowel syndrome.
Siddiqui S; Cash BD
Drugs Today (Barc); 2020 Mar; 56(3):203-210. PubMed ID: 32282867
[TBL] [Abstract][Full Text] [Related]
10. Tenapanor: First Approval.
Markham A
Drugs; 2019 Nov; 79(17):1897-1903. PubMed ID: 31677150
[TBL] [Abstract][Full Text] [Related]
11. A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers.
Johansson S; Rosenbaum DP; Knutsson M; Leonsson-Zachrisson M
Clin Exp Nephrol; 2017 Jun; 21(3):407-416. PubMed ID: 27368672
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, Safety, and Tolerability of Tenapanor in Healthy Chinese and Caucasian Volunteers: A Randomized, Open-Label, Single-Center, Placebo-Controlled Phase 1 Study.
Yuan G; Chen Y; Li L; Wang X; Wei G; Zeng J; Hui AM; Jiang Y; Zhao H; Diao L; Zhou Y; Xiao Y; Chen M
Int J Clin Pract; 2024; 2024():1386980. PubMed ID: 38481823
[TBL] [Abstract][Full Text] [Related]
13. NHE3 inhibitor tenapanor maintains intestinal barrier function, decreases visceral hypersensitivity, and attenuates TRPV1 signaling in colonic sensory neurons.
King AJ; Chang L; Li Q; Liu L; Zhu Y; Pasricha PJ; Wang J; Siegel M; Caldwell JS; Edelstein S; Rosenbaum DP; Kozuka K
Am J Physiol Gastrointest Liver Physiol; 2024 May; 326(5):G543-G554. PubMed ID: 38252683
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis.
Black CJ; Burr NE; Quigley EMM; Moayyedi P; Houghton LA; Ford AC
Gastroenterology; 2018 Dec; 155(6):1753-1763. PubMed ID: 30144426
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: pooled Phase 3 analysis.
Nee JW; Johnston JM; Shea EP; Walls CE; Tripp K; Shiff S; Fox SM; Bochenek W; Weissman D; Currie MG; Lembo AJ
Expert Rev Gastroenterol Hepatol; 2019 Apr; 13(4):397-406. PubMed ID: 30791771
[TBL] [Abstract][Full Text] [Related]
16. Tenapanor in the Treatment of Irritable Bowel Syndrome with Constipation: Discovery, Efficacy, and Role in Management.
Herekar A; Shimoga D; Jehangir A; Shahsavari D; Yan Y; Karunaratne TB; Sharma A
Clin Exp Gastroenterol; 2023; 16():79-85. PubMed ID: 37309470
[TBL] [Abstract][Full Text] [Related]
17. Tenapanor administration and the activity of the H
Johansson S; Rosenbaum DP; Palm J; Stefansson B; Knutsson M; Lisbon EA; Hilgendorf C
Br J Clin Pharmacol; 2017 Sep; 83(9):2008-2014. PubMed ID: 28432691
[TBL] [Abstract][Full Text] [Related]
18. Effect of Tenapanor on Interdialytic Weight Gain in Patients on Hemodialysis.
Block GA; Rosenbaum DP; Leonsson-Zachrisson M; Stefansson BV; Rydén-Bergsten T; Greasley PJ; Johansson SA; Knutsson M; Carlsson BC
Clin J Am Soc Nephrol; 2016 Sep; 11(9):1597-1605. PubMed ID: 27340281
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics, Safety, and Tolerability of the NHE3 Inhibitor Tenapanor: Two Trials in Healthy Volunteers.
Rosenbaum DP; Yan A; Jacobs JW
Clin Drug Investig; 2018 Apr; 38(4):341-351. PubMed ID: 29363027
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial.
Block GA; Rosenbaum DP; Yan A; Chertow GM
J Am Soc Nephrol; 2019 Apr; 30(4):641-652. PubMed ID: 30846557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
